Zobrazeno 1 - 10 of 129 pro vyhledávání: '"Anne M, Traynor"'
1
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029
Autor: Tareq Salous, Nikhil A. Shukla, Sandra K. Althouse, Susan M. Perkins, Muhammad Furqan, Ticiana Leal, Anne M. Traynor, Lawrence E. Feldman, Nasser H. Hanna, Greg A. Durm
Publikováno v: Cancer. 129:264-271
Immunotherapy using a checkpoint inhibitor (CPI) alone or in combination with chemotherapy is the standard of care for treatment-naive patients with advanced non-small cell lung cancer (NSCLC) without driver mutations for which targeted therapies hav
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e399874bfa899b590a2d4c6565f72217
https://doi.org/10.1002/cncr.34565
Zobrazit plný text záznamu
2
Akademický článek
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Autor: Jennifer L Schehr, Zachery D Schultz, Jay W Warrick, David J Guckenberger, Hannah M Pezzi, Jamie M Sperger, Erika Heninger, Anwaar Saeed, Ticiana Leal, Kara Mattox, Anne M Traynor, Toby C Campbell, Scott M Berry, David J Beebe, Joshua M Lang
Publikováno v: PLoS ONE, Vol 11, Iss 7, p e0159397 (2016)
Expression of programmed-death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) is typically evaluated through invasive biopsies; however, recent advances in the identification of circulating tumor cells (CTCs) may be a less invasive method to
Externí odkaz: https://doaj.org/article/8f6661b01ec84d04955efc3f9136e5d9
Zobrazit plný text záznamu
3
Overcoming Barriers: Evidence-Based Strategies to Increase Enrollment of Underrepresented Populations in Cancer Therapeutic Clinical Trials—a Narrative Review
Autor: Joshua Wright, Iris Vuong, Anne M. Traynor, Tracy M. Downs, Rick Strickland, Amanda T. Eggen, Erin Bailey, Margaret B Nolan
Publikováno v: Journal of Cancer Education. 35:841-849
Disparities in cancer incidence and mortality rates among racial and ethnic minorities (African Americans, Asian Americans, Pacific Islanders, American Indians, and Latinos/Hispanic Americans) in the USA are well documented. Enrollment of underrepres
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b95a9d9354fdc91922000698c5b672b
https://doi.org/10.1007/s13187-019-01650-y
Zobrazit plný text záznamu
4
Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection
Autor: Justin D. Blasberg, Song Chen, Christopher W. Seder, Robert Jeraj, Stephanie Harmon, Anne M. Traynor
Publikováno v: Journal of Thoracic Disease. 11:1106-1116
Background: Preoperative identification of non-small cell lung cancer (NSCLC) patients at risk for disease recurrence has proven unreliable. The extraction of quantitative metrics from imaging based on tumor intensity and texture may enhanced disease
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9560cf3632170d269d4568986b43921d
https://doi.org/10.21037/jtd.2019.04.46
Zobrazit plný text záznamu
5
Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396
Autor: Fatemeh Ardeshir-Larijani, Nisha Anjali Mohindra, Anne M. Traynor, Jyoti Malhotra, Elaine Shum, Patrick C. Ma, Nasser H. Hanna
Publikováno v: Journal of Clinical Oncology. 40:TPS8592-TPS8592
TPS8592 Background: A standard of care treatment for most patients with stage II and III non-small cell lung cancer (NSCLC) and a PD-L1 > 1% is surgery followed by adjuvant (adj) histology-specific chemotherapy followed by 1 year of atezolizumab. The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bdbbd6970725ea063fb46568e25d07b6
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8592
Zobrazit plný text záznamu
8
Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center
Autor: Kari B. Wisinski, Anne M. Traynor, Jill M. Kolesar, Noelle K. LoConte, Jeff A. Engle, Toby C. Campbell, G. Wilding, Glenn Liu
Publikováno v: Journal of Oncology Pharmacy Practice. 24:348-353
Background/Aims Oral chemotherapy is increasingly utilized leaving the patient responsible for self-administering an often complex regimen where adverse effects are common. Non-adherence and reduced relative dose intensity are both associated with po
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a92ef230206bb8894c0a1437ac7469f6
https://doi.org/10.1177/1078155217704989
Zobrazit plný text záznamu
10
Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study
Autor: Robert Hegeman, Dhimant Patel, Leah L. Dietrich, Wei Xu, Anne M. Traynor, KyungMann Kim, Sandeep Saha, Amye J. Tevaarwerk, Mark E. Burkard, Josephine Harter, Kari B. Wisinski, Jules H. Blank
Publikováno v: Clinical Breast Cancer. 16:256-261
Background Estrogen receptor beta (ERβ) is expressed by 50% to 80% of triple-negative breast cancers (TNBC). Agonism of ERβ has antiproliferative effects in TNBC cells expressing ERβ. This phase 2 study evaluated single-agent high-dose estradiol i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eed2ecca3ea1e524843ef5f5588ade70
https://doi.org/10.1016/j.clbc.2016.03.005
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje